Private company

Eiger BioPharmaceuticals, Inc.

Biological products company.

Last updated Oct 18, 2026.

Overview

IndustryBiological Products, (No Diagnostic Substances)
Business address2155 Park Boulevard, Palo Alto, Ca 94306²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-455.1%Operating margin³

-475.3%Net margin³

17.0%Revenue growth, 2023³

-$74.8MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2023

Research and developmentSelling, general and admin

Cost of revenue0¢$24.0K
Research and development67¢$62.3M
Selling, general and admin27¢$25.2M
Interest6¢$5.5M
Income tax0¢$6.0K

Out of $15.8M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴³$15.8M in 2023

Operating income⁵⁶⁷⁴³-$71.8M in 2023+73% since 2017

Net income⁵⁶⁷⁴³-$75.0M in 2023+77% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Revenue				$0⁴	$12.1M⁴	$13.5M³	$15.8M³
Cost of revenue				$0⁴	$745.0K⁴	$1.8M³	$24.0K³
Research and development	$29.5M⁵	$37.1M⁶	$51.8M⁷	$41.6M⁴	$64.4M⁴	$75.3M³	$62.3M³
Selling, general and admin			$17.1M⁷	$20.6M⁴	$23.9M⁴	$29.1M³	$25.2M³
Operating income	-$41.5M⁵	-$51.0M⁶	-$68.9M⁷	-$62.1M⁴	-$76.9M⁴	-$92.7M³	-$71.8M³
Interest	$1.5M⁵	$2.3M⁶	$3.4M⁷	$3.6M⁴	$3.6M⁴	$4.1M³	$5.5M³
Income tax	$0⁵	$0⁶	$0⁷	$0⁴	$64.0K⁴	$23.0K³	$6.0K³
Net income	-$42.4M⁵	-$52.4M⁶	-$70.3M⁷	-$65.1M⁴	-$33.9M⁴	-$96.8M³	-$75.0M³
Earnings per share				-$2.31⁴	-$1.00⁴	-$69.74³	-$50.78³
Earnings per share (diluted)				-$2.31⁴	-$1.00⁴	-$69.74³	-$50.78³

Total assets¹⁰⁵⁶⁷⁴³$38.8M in 2023−9% since 2017

Total liabilities¹⁰⁵⁶⁷⁴³$53.3M in 2023+162% since 2017

Shareholders’ equity⁶⁷⁴³-$14.5M in 2023

Cash¹⁰⁵⁶⁷⁴³$25.4M in 2023−21% since 2017

Long-term debt¹⁰⁵⁶⁷⁴³$0 in 2023

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash	$32.0M¹⁰	$61.3M⁵	$39.4M⁶	$28.9M⁷	$22.2M⁴	$25.8M³	$25.4M³
Current assets	$42.5M¹⁰	$101.8M⁵	$100.4M⁶	$137.8M⁷	$103.4M⁴	$117.5M³	$37.8M³
Total assets	$42.9M¹⁰	$102.4M⁵	$105.1M⁶	$143.6M⁷	$126.4M⁴	$120.1M³	$38.8M³
Current liabilities	$7.3M¹⁰	$10.0M⁵	$16.9M⁶	$16.6M⁷	$29.9M⁴	$25.1M³	$53.3M³
Long-term debt	$13.1M¹⁰	$25.6M⁵	$30.4M⁶	$31.2M⁷	$24.0M⁴	$39.6M³	$0³
Total liabilities	$20.4M¹⁰	$35.9M⁵	$48.7M⁶	$48.6M⁷	$54.0M⁴	$64.8M³	$53.3M³
Shareholders’ equity	$22.5M⁶	$66.6M⁷	$56.5M⁴	$95.0M⁴	$72.4M³	$55.3M³	-$14.5M³
Shares outstanding	10.5M shares¹⁰	19.2M shares⁵	24.5M shares⁶	33.9M shares⁷	34.6M shares⁴	1.5M shares³	1.5M shares³

Cash from operations⁵⁶⁷⁴³-$74.5M in 2023+94% since 2017

Capital spending⁵⁶⁷⁴³$234.0K in 2023+432% since 2017

Free cash flow⁵⁶⁷⁴³-$74.8M in 2023+95% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash from operations	-$38.4M⁵	-$42.7M⁶	-$63.6M⁷	-$63.2M⁴	-$71.3M⁴	-$83.0M³	-$74.5M³
Capital spending	$44.0K⁵	$142.0K⁶	$475.0K⁷	$258.0K⁴	$225.0K⁴	$340.0K³	$234.0K³
Free cash flow	-$38.4M	-$42.8M	-$64.1M	-$63.4M	-$71.6M	-$83.3M	-$74.8M

Compare Eiger BioPharmaceuticals, Inc. with another company

Leadership

Who has led Eiger BioPharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

David Apelian2018–2019

201520202025

Chief executive officerDavid Apelian Feb 2, 2023 to Jul 6, 2023¹¹
Chief executive officerDavid A. Cory Mar 28, 2016 to Mar 11, 2022¹²
Chief executive officerKrisztina M. Zsebo Jan 29, 2014 to Apr 7, 2015¹³
PresidentDavid A. Cory Mar 28, 2016 to Mar 11, 2022¹²
PresidentKrisztina M. Zsebo Jan 29, 2014 to Jan 29, 2014¹³
PresidentPaul B. Cleveland Jun 20, 2014 to Jan 5, 2015¹⁴
Chief financial officerWilliam G. Kachioff Apr 14, 2023 to Apr 14, 2023¹⁵
Chief financial officerSriram Ryali Dec 27, 2018 to Mar 14, 2022¹⁶
Chief financial officerJames H. Welch Mar 25, 2016 to Mar 16, 2018¹⁷
Chief financial officerPaul B. Cleveland Jun 20, 2014 to Jan 5, 2015¹⁴
Chief operating officerDavid Apelian Jan 9, 2018 to Mar 26, 2019¹⁸

Board members and other officers (34)

Chief Business OfficerIngrid Choong Sep 5, 2023 to Sep 5, 2023¹⁹
GC & Chief Compliance OfficerErik Atkisson Oct 1, 2021 to Jan 30, 2023²⁰
Ex VP & Chief Commerc. OfficerEldon C. Mayer Iii. Jan 30, 2020 to Mar 21, 2023²¹
OfficerStephana Eilene Patton Mar 25, 2019 to Mar 15, 2021²²
SVP, Liver and Infectious DiseEduardo Bruno Martins Mar 25, 2016 to Mar 14, 2017²³
Chief Business OfficerJames P. Shaffer Mar 25, 2016 to Mar 15, 2021²⁴
Chief Medical OfficerJoanne Quan Mar 25, 2016 to Apr 4, 2018²⁵
OfficerAndrew C. Jackson Mar 17, 2015 to Mar 17, 2015²⁶
VP Corp Dvlpmnt & Invs RltnsFredrik Wiklund Jan 29, 2014 to Jan 5, 2015²⁷
VP Clinical OperationsJeffrey J. Rudy Jan 29, 2014 to Jan 12, 2015²⁸
VP Finance & AdministrationRebecque J. Laba Jan 29, 2014 to Apr 3, 2015²⁹
VP ManufacturingRyan K. Takeya Jan 29, 2014 to Apr 3, 2015³⁰
Board memberLisa Kelly-Croswell Jul 19, 2022 to Mar 3, 2023³¹
Board memberKim Sablich Apr 23, 2021 to Mar 3, 2023³²
Board memberChristine Murray Jan 9, 2019 to Mar 3, 2023³³
Board memberAmit Sachdev May 30, 2019 to Mar 3, 2023³⁴
Board memberEldon C. Mayer Iii. Jan 9, 2018 to Mar 25, 2019³⁵
Board memberDavid Apelian Jun 20, 2017 to Jul 6, 2023³⁶
Board memberEvan Loh Sep 18, 2017 to Mar 3, 2023³⁷
Board memberCharles Bramlage Mar 25, 2016 to Apr 13, 2017³⁸
Board memberEdgar Engleman Mar 25, 2016 to Apr 13, 2017³⁹
Board memberJeffrey S. Glenn Mar 25, 2016 to Mar 3, 2023⁴⁰
Board memberDavid A. Cory Mar 28, 2016 to Mar 11, 2022¹²
Board memberNina S. Kjellson Mar 31, 2016 to Apr 14, 2017⁴¹
Board memberBarbara Dalton Jan 29, 2014 to Jan 29, 2014⁴²
Board memberGraham K. Cooper Jan 29, 2014 to Jun 5, 2015⁴³
Board memberJohan Kordel Jan 29, 2014 to Feb 6, 2014⁴⁴
Board memberKrisztina M. Zsebo Jan 29, 2014 to Apr 7, 2015¹³
Board memberGregg H. Alton Jan 30, 2014 to Jun 5, 2015⁴⁵
Board memberMichael Narachi Jan 30, 2014 to Jun 5, 2015⁴⁶
Board memberPatrick Y. Yang Mar 4, 2014 to May 21, 2014⁴⁷
Board memberPeter Honig Mar 4, 2014 to Jun 5, 2015⁴⁸
General counselJames Vollins Apr 14, 2023 to May 2, 2023⁴⁹
General counselElizabeth E. Reed Jun 11, 2014 to Jan 5, 2015⁵⁰

Former names

Celladon CorpOct 5, 2004 to Mar 23, 2016²

Timeline

Feb 2, 2023New chief executive David Apelian becomes CEO¹¹
Mar 28, 2016New chief executive David A. Cory becomes CEO¹²
Jan 29, 2014New chief executive Krisztina M. Zsebo becomes CEO¹³

Filings

148 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 48 major events, 45 insider forms, 20 large holders, 24 other. The latest 20:

Oct 1, 202415-12G EDGAR
Oct 1, 20248-K EDGAR
Sep 9, 20248-K EDGAR
Sep 4, 20248-K EDGAR
Sep 3, 20248-K EDGAR
Aug 26, 2024SC 13G EDGAR
Aug 2, 20248-K EDGAR
Aug 1, 20248-K EDGAR
Jul 16, 20248-K EDGAR
Jul 10, 20248-K EDGAR
Jul 1, 20248-K EDGAR
Jul 1, 2024SC 13D/A EDGAR
Jun 21, 20248-K EDGAR
Jun 14, 20248-K EDGAR
May 28, 20248-K EDGAR
May 8, 20248-K EDGAR
May 2, 20248-K EDGAR
Apr 29, 202410-K/A EDGAR
Apr 25, 202425-NSE EDGAR
Apr 8, 202410-K EDGAR

The 148 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 20 such filings since October 2021, the latest 10:

Aug 26, 2024SC 13G
Jul 1, 2024SC 13D/A
Feb 14, 2024SC 13G/A
Dec 4, 2023SC 13D/A
Nov 24, 2023SC 13D
Nov 3, 2023SC 13D/A
Oct 20, 2023SC 13D
Sep 28, 2023SC 13G/A
Aug 15, 2023SC 13G
Jul 7, 2023SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREiger BioPharmaceuticals, Inc. filings on SEC EDGAR
2
SEC EDGAREiger BioPharmaceuticals, Inc. filings on SEC EDGAR
3
SEC EDGAREiger BioPharmaceuticals, Inc. 10-K for fiscal 2023
4
SEC EDGAREiger BioPharmaceuticals, Inc. 10-K for fiscal 2020
5
SEC EDGAREiger BioPharmaceuticals, Inc. 10-K for fiscal 2017
6
SEC EDGAREiger BioPharmaceuticals, Inc. 10-K for fiscal 2018
7
SEC EDGAREiger BioPharmaceuticals, Inc. 10-K for fiscal 2019
8
SEC EDGAREiger BioPharmaceuticals, Inc. 10-Q for fiscal 2023
9
SEC EDGAREiger BioPharmaceuticals, Inc. 10-Q for fiscal 2023
10
SEC EDGAREiger BioPharmaceuticals, Inc. 10-K for fiscal 2017
11
SEC EDGARDavid Apelian, Chief executive officer
12
SEC EDGARDavid A. Cory, Chief executive officer
13
SEC EDGARKrisztina M. Zsebo, Chief executive officer
14
SEC EDGARPaul B. Cleveland, President
15
SEC EDGARWilliam G. Kachioff, Chief financial officer
16
SEC EDGARSriram Ryali, Chief financial officer
17
SEC EDGARJames H. Welch, Chief financial officer
18
SEC EDGARDavid Apelian, Chief operating officer
19
SEC EDGARIngrid Choong, Chief Business Officer
20
SEC EDGARErik Atkisson, GC & Chief Compliance Officer
21
SEC EDGAREldon C. Mayer Iii., Ex VP & Chief Commerc. Officer
22
SEC EDGARStephana Eilene Patton, Officer
23
SEC EDGAREduardo Bruno Martins, SVP, Liver and Infectious Dise
24
SEC EDGARJames P. Shaffer, Chief Business Officer
25
SEC EDGARJoanne Quan, Chief Medical Officer
26
SEC EDGARAndrew C. Jackson, Officer
27
SEC EDGARFredrik Wiklund, VP Corp Dvlpmnt & Invs Rltns
28
SEC EDGARJeffrey J. Rudy, VP Clinical Operations
29
SEC EDGARRebecque J. Laba, VP Finance & Administration
30
SEC EDGARRyan K. Takeya, VP Manufacturing
31
SEC EDGARLisa Kelly-Croswell, Board member
32
SEC EDGARKim Sablich, Board member
33
SEC EDGARChristine Murray, Board member
34
SEC EDGARAmit Sachdev, Board member
35
SEC EDGAREldon C. Mayer Iii., Board member
36
SEC EDGARDavid Apelian, Board member
37
SEC EDGAREvan Loh, Board member
38
SEC EDGARCharles Bramlage, Board member
39
SEC EDGAREdgar Engleman, Board member
40
SEC EDGARJeffrey S. Glenn, Board member
41
SEC EDGARNina S. Kjellson, Board member
42
SEC EDGARBarbara Dalton, Board member
43
SEC EDGARGraham K. Cooper, Board member
44
SEC EDGARJohan Kordel, Board member
45
SEC EDGARGregg H. Alton, Board member
46
SEC EDGARMichael Narachi, Board member
47
SEC EDGARPatrick Y. Yang, Board member
48
SEC EDGARPeter Honig, Board member
49
SEC EDGARJames Vollins, General counsel
50
SEC EDGARElizabeth E. Reed, General counsel